Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
60.3M
-
Number of holders
-
54
-
Total 13F shares, excl. options
-
30.5M
-
Shares change
-
-94K
-
Total reported value, excl. options
-
$362M
-
Value change
-
-$1.13M
-
Put/Call ratio
-
0.08
-
Number of buys
-
28
-
Number of sells
-
-19
-
Price
-
$11.87
Significant Holders of Janux Therapeutics, Inc. - Common Stock (JANX) as of Q2 2023
61 filings reported holding JANX - Janux Therapeutics, Inc. - Common Stock as of Q2 2023.
Janux Therapeutics, Inc. - Common Stock (JANX) has 54 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.5M shares
of 60.3M outstanding shares and own 50.56% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (8.67M shares), FMR LLC (5.06M shares), BVF INC/IL (4.11M shares), ORBIMED ADVISORS LLC (2.84M shares), CITADEL ADVISORS LLC (2.12M shares), JANUS HENDERSON GROUP PLC (2.11M shares), BlackRock Inc. (1.19M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (900K shares), VANGUARD GROUP INC (762K shares), and EcoR1 Capital, LLC (453K shares).
This table shows the top 54 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.